Literature DB >> 20598622

Classifying risk factors for dyskinesia in Parkinson's disease.

J C Sharma1, C G Bachmann, G Linazasoro.   

Abstract

BACKGROUND: Currently there is no classification of risk factors applicable to an individual patient with Parkinson's disease for the development of dyskinesia.
METHODS: We conducted literature search to identify and classifying risk factors into groups - (a) intrinsic vs extrinsic and (b) modifiable vs non-modifiable.
RESULTS: Younger age, young age of onset and severity of PD are major intrinsic non-modifiable risk factors for dyskinesia, female gender is another factor but not independent of other factors. Genetic expression and plasticity may determine pre-disposition to age of onset of PD and dyskinesia, these are currently non-modifiable factors arising due to an interaction of intrinsic and extrinsic factors. Lower initial body weight and weight loss during the course of the disease increase the risk of dyskinesia. Levodopa dose per kilogram body weight is a more significant risk factor than absolute levodopa dose. Early use of longer acting non-levodopa (i.e. dopamine agonists) medications delays the onset of dyskinesia. Interaction between body weight, levodopa dose and mode and duration of drug delivery is a significant modifiable factor.
CONCLUSION: Dyskinesia in PD arises as a consequence of the interaction of intrinsic versus extrinsic and modifiable versus non-modifiable factors. Identification and manipulation of modifiable factors for an individual patient may reduce the risk and burden of dyskinesia. Adjustment of levodopa dose according to body weight during the course of the disease seems to be a significant modifiable risk factor for dyskinesia.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20598622     DOI: 10.1016/j.parkreldis.2010.06.003

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  20 in total

Review 1.  Modern treatment in Parkinson's disease, a personal approach.

Authors:  Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-21       Impact factor: 3.575

2.  Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?

Authors:  Seok Jong Chung; Han Soo Yoo; Hye Sun Lee; Hyo Eun Jeong; Soo-Jong Kim; Jungsu S Oh; Jae Seung Kim; Young H Sohn; Phil Hyu Lee
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

3.  Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.

Authors:  Erinaldo Ubirajara Damasceno Dos Santos; Elaine Bandeira Cavalcanti Duarte; Laura Maria Ramos Miranda; Andore Guescel C Asano; Nadja Maria Jorge Asano; Maria de Mascena Diniz Maia; Paulo Roberto Eleutério de Souza
Journal:  Neuromolecular Med       Date:  2019-05-22       Impact factor: 3.843

4.  The impact of early versus late levodopa administration.

Authors:  Gilad Yahalom; Oren S Cohen; Naama Warmann-Alaluf; Chen Shabat; Hanna Strauss; Sandra Elincx-Benizri; Simon Israeli-Korn; Esther Stein; Lior Greenbaum; Sharon Hassin-Baer
Journal:  J Neural Transm (Vienna)       Date:  2016-12-21       Impact factor: 3.575

5.  Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.

Authors:  Alessandra Nicoletti; Giovanni Mostile; Giuseppe Nicoletti; Gennarina Arabia; Giovanni Iliceto; Paolo Lamberti; Roberto Marconi; Letterio Morgante; Paolo Barone; Aldo Quattrone; Mario Zappia
Journal:  J Neurol       Date:  2016-03-10       Impact factor: 4.849

Review 6.  Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.

Authors:  Tai N Tran; Trang N N Vo; Karen Frei; Daniel D Truong
Journal:  J Neural Transm (Vienna)       Date:  2018-07-03       Impact factor: 3.575

7.  Gender effect on time to levodopa-induced dyskinesias.

Authors:  Sharon Hassin-Baer; Irena Molchadski; Oren S Cohen; Zeev Nitzan; Lilach Efrati; Olga Tunkel; Evgenia Kozlova; Amos D Korczyn
Journal:  J Neurol       Date:  2011-05-01       Impact factor: 4.849

Review 8.  The relevance of gender in Parkinson's disease: a review.

Authors:  Marina Picillo; Alessandra Nicoletti; Vincenza Fetoni; Barbara Garavaglia; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neurol       Date:  2017-01-04       Impact factor: 4.849

Review 9.  Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

10.  Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.

Authors:  Erinaldo Ubirajara Damasceno Dos Santos; Isaura Isabelle Fonseca Gomes da Silva; Amdore Guescel C Asano; Nadja Maria Jorge Asano; Maria De Mascena Diniz Maia; Paulo Roberto Eleutério de Souza
Journal:  Mol Biol Rep       Date:  2020-11-05       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.